XRlabs

Device-agnostic AI software layer for surgical intelligence, connecting operating room equipment for real-time support.

Cover Block

Public sources

Field	Value
Company	XRlabs
Tagline	Device-agnostic AI software layer for surgical intelligence, connecting operating room equipment for real-time support [Business Wire, October 2026] [xrlabs.ai, retrieved]
Headquarters	London, United Kingdom [Business Wire, October 2026]
Founded	2021 [Business Wire, October 2026]
Stage	Seed [Business Wire, October 2026]
Business model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth profile	Venture Scale
Founding team	Solo Founder
Founder	Dr. Ali Haddad [Business Wire, October 2026]
Funding label	Seed
Total disclosed funding	$8,400,000 [Business Wire, October 2026] [Axios, October 2026]

Executive Summary

PUBLIC XRlabs is building a device-agnostic AI software layer for operating rooms, and it merits attention now because the company paired that thesis with an $8.4 million seed round in October 2026 led by Playground Global, a timing signal that the surgical workflow category is beginning to attract institution-grade capital [Business Wire, October 2026] [Axios, October 2026]. Founded in London in 2021, the company presents itself as an attempt to fix a familiar operating-room problem: fragmented devices, split surgeon attention, and limited real-time synthesis across video, imaging, and navigation systems [xrlabs.ai, retrieved] [Business Wire, October 2026].

The product story is straightforward on paper, if still early in public proof: XRlabs says its software runs on equipment hospitals already own, with XRlabs SIM focused on turning CT and MRI scans into interactive 3D planning models and SurgicalOS focused on creating an anatomy-aware intraoperative view from multiple data sources [xrlabs.ai, retrieved] [xrlabs.ai, retrieved]. That integration-first positioning matters because it suggests a lower-friction adoption path than full hardware replacement, although the current public record is still weighted toward company descriptions rather than independent technical validation [xrlabs.ai, retrieved] [Citybiz, October 2026].

The founder profile is one of the more credible parts of the early narrative. Dr. Ali Haddad is identified as founder and CEO, and public materials describe him as a neurosurgeon, while Omar Ishrak, the former Medtronic chairman and CEO, joined as chair of the board alongside the seed financing [LinkedIn, retrieved 2026] [Business Wire, October 2026].

Commercially, XRlabs appears to be pursuing a hardware-plus-software model in surgical environments, though the revenue mix, pricing structure, and procurement motion are not yet visible in public materials [Business Wire, October 2026] [xrlabs.ai, retrieved]. The main traction datapoint disclosed so far is reported use in more than 100 surgical cases across three continents, repeated across several outlets, which is notable as evidence of real-world exposure but still short of the adoption detail investors would want around repeat usage, named hospital systems, and paid deployment scope [Business Wire, October 2026] [MobiHealthNews] [MPO-Mag].

Over the next 12 to 18 months, the watch items are disciplined rather than speculative: regulatory progress in the UK, Europe, and the US, expansion of clinical evidence, and whether XRlabs can convert surgeon enthusiasm into durable hospital workflows and referenceable enterprise accounts [Business Wire, October 2026] [Citybiz, October 2026]. The company has assembled a credible early story around workflow integration, founder-market fit, and strategic board support; the remaining question is whether that story translates into repeatable deployment economics in a conservative care setting.

Lightly corroborated -- Section relies on two independent reports for the seed round and board appointment, but several product and traction details remain primarily company-described or only partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed, total disclosed approximately $8.4 million

How the Company Got Here

Public sources XRlabs presents itself as a London-based surgical technology company trying to solve a practical operating room problem: too many devices, too little shared context at the point of care [xrlabs.ai, retrieved]. Public materials place the company in London and show a 2021 founding date, with Dr. Ali Haddad named as founder and CEO on the company site [xrlabs.ai, retrieved]. The framing matters because the company is not describing a new surgical robot or a replacement hardware stack, but an intelligence layer that sits across equipment hospitals already own [xrlabs.ai, retrieved].

The chronology that can be supported cleanly from company and company-adjacent public records is still short. XRlabs' website highlights XRlabs SIM, a planning product that converts scans into interactive 3D models, and SurgicalOS, which the company describes as an anatomy-aware operating room view built from connected devices [xrlabs.ai, retrieved]. In October 2025, the company said XRlabs SIM was named to TIME's Best Inventions of 2025, a useful visibility milestone even if it does not by itself validate clinical adoption [TIME, October 2025].

The clearest financing milestone arrived on October 19, 2026, when XRlabs announced an $8.4 million seed round led by Playground Global with participation from Eka Ventures [xrlabs.ai, retrieved]. Around the same announcement window, the company also publicized Omar Ishrak, former Medtronic chairman and CEO, joining as chair of the board, which is a notable governance signal for a seed-stage surgical software company [xrlabs.ai, retrieved]. What remains less settled from public company materials alone is the legal entity structure and any earlier financing history, so the current public record supports a narrow view: a 2021 London-founded company, built around surgical intelligence software, with a first disclosed institutional financing in late 2026 [xrlabs.ai, retrieved].

Company-stated, unverified -- This section relies primarily on company website materials, with partial corroboration from the TIME-related company post.

Product and Technology

MIXED

XRlabs is positioning itself as an operating-room software layer, not as a replacement for incumbent surgical hardware. The company describes its core concept as "Surgical Intelligence": device-agnostic AI that runs on equipment hospitals already own, connects OR devices into a single anatomy-aware system, and is intended to reduce the fragmentation that comes from separate imaging, navigation, and visualization tools [xrlabs.ai, retrieved] [Business Wire, October 2026]. That framing is consistent across the company site and seed-round coverage, although the underlying performance claims remain largely company-described rather than independently benchmarked [Citybiz, October 2026] [Axios, October 2026].

The product surface appears to have at least two named components. XRlabs SIM is described by the company as a planning and rehearsal tool that converts CT and MRI scans into interactive 3D digital twins, and XRlabs says the product was named to TIME's Best Inventions of 2025 [xrlabs.ai, retrieved] [TIME, October 2025]. SurgicalOS is presented as the intraoperative layer, combining scope video, navigation, and imaging into an anatomy-aware view during surgery [xrlabs.ai, retrieved]. Public reporting also ties the platform to more than 100 surgical cases across three continents as of October 2026, but that usage figure traces back to company statements carried by publishers rather than to hospital-level case logs or peer-reviewed outcomes data [Business Wire, October 2026] [MobiHealthNews, retrieved 2026] [MPO-Mag, retrieved 2026].

A second point worth separating is capability from evidence. XRlabs and syndicated coverage say the technology was used to design patient-specific skull implants for the separation of craniopagus twins, including real-time 3D overlays derived from CT data in a mixed-reality environment [Yahoo Finance, retrieved 2026] [Morningstar, retrieved 2026]. That is a credible signal that the software can support high-acuity surgical planning, but it does not yet establish broad clinical generalizability, regulatory clearance scope, or repeatable workflow gains across a wider set of procedures based on the public record reviewed here [XRlabs, retrieved 2026] [Business Wire, October 2026].

Company-stated, unverified -- Core product descriptions and case-usage claims rely materially on company website and company-originated announcements, with partial corroboration from syndicated and news coverage.

Where the Demand Sits

PUBLIC The market matters now because hospitals are under pressure to make complex operating rooms more productive without replacing installed equipment, and XRlabs is positioning itself against that bottleneck rather than against a single procedure category [xrlabs.ai, retrieved] [Business Wire, October 2026].

The hard part is that no third-party market sizing report is present in the supplied record for XRlabs’ precise category, which sits between surgical software, imaging, navigation, and operating room workflow. Public evidence supports the problem statement more cleanly than the TAM. XRlabs argues that the operating room is "data-rich and insight-poor," and its website cites a literature reference that 10% of operative time is lost to manual scope adjustment in neurosurgery settings [xrlabs.ai, retrieved]. That does not establish market size, but it does point to a cost center with real economic weight if the workflow issue generalizes beyond a narrow set of cranial procedures [xrlabs.ai, retrieved].

Demand drivers in the public record are practical rather than theoretical. XRlabs’ core pitch is a device-agnostic software layer that runs on equipment hospitals already own, which lowers the implied adoption hurdle relative to full equipment replacement and aligns with capital-constrained provider environments [xrlabs.ai, retrieved] [Business Wire, October 2026]. The company also says the platform has been used in more than 100 surgical cases across three continents, a small sample in absolute terms but enough to suggest early cross-border clinical interest rather than a single-site pilot [Business Wire, October 2026] [MobiHealthNews].

Adjacent markets are easier to identify than the exact core market. XRlabs SIM sits near preoperative planning and 3D surgical simulation through its use of CT and MRI-based digital twins, while SurgicalOS appears closer to intraoperative imaging integration, navigation, and visualization software [xrlabs.ai, retrieved]. Substitute budgets may therefore come from surgical navigation systems, advanced imaging software, mixed-reality planning tools, and OR workflow platforms, which matters because purchasing decisions may be made by service-line leaders or device partners rather than a standalone AI budget line [xrlabs.ai, retrieved] [Citybiz, October 2026].

Regulatory and macro forces cut both ways. The October 2026 funding announcement says XRlabs plans regulatory work across the United Kingdom, Europe, and the United States, which is a necessary signal for a company influencing intraoperative decision support, but it also implies a longer commercialization path than a planning-only software tool would face [Business Wire, October 2026]. At the same time, board leadership from former Medtronic chief executive Omar Ishrak suggests the company understands that medtech adoption is often governed by evidence generation, workflow fit, and channel relationships as much as product performance [Business Wire, October 2026].

Cited market signal	What it suggests for demand	Source
10% of operative time lost to manual scope adjustment in cited neurosurgery literature surfaced on XRlabs site	Workflow inefficiency can carry measurable cost inside high-cost OR time	[xrlabs.ai, retrieved]
100+ surgical cases across three continents	Early evidence of cross-geography applicability, though still company-reported	[Business Wire, October 2026] [MobiHealthNews]
Regulatory expansion planned across UK, Europe, and U.S.	Management expects the addressable market to be international and regulated	[Business Wire, October 2026]
Device-agnostic deployment on installed equipment	Budget may come from software and workflow optimization rather than equipment refresh cycles	[xrlabs.ai, retrieved] [Citybiz, October 2026]

The table shows why the market case is plausible even without a clean third-party TAM figure in hand. Public sources support a real workflow problem, a broad enough adjacency map, and a commercialization path tied to existing OR infrastructure, but they do not yet support a quantified claim on category size.

Lightly corroborated -- Relies on company materials for market framing, with partial corroboration from Business Wire, Citybiz, and MobiHealthNews on deployment scope and regulatory intent.

Competitive Landscape

MIXED XRlabs is positioning itself less as a replacement for surgical hardware and more as an interoperability layer that sits across the operating room stack, which places it in competition with incumbent device ecosystems, planning software vendors, and in-house hospital workflows rather than with one clean peer set alone [xrlabs.ai, retrieved] [Business Wire, October 2026].

The competitive map is easiest to read in segments. At the equipment layer, the practical alternatives are incumbent surgical-platform and imaging vendors whose systems already sit inside the OR, including companies tied to endoscopy, navigation, and intraoperative imaging workflows; XRlabs' own framing is that OR devices "run in isolation" and that its software can connect equipment hospitals already own, which implies the initial wedge is against fragmented incumbent stacks rather than against greenfield software budgets [xrlabs.ai, retrieved]. At the planning layer, XRlabs SIM competes more indirectly with established preoperative imaging and 3D planning workflows, including the status quo of CT and MRI review on standard clinical software, because the company's claim is that SIM turns those scans into interactive digital twins for rehearsal and planning [xrlabs.ai, retrieved]. The adjacent substitute is still manual coordination by surgeons and staff, especially where hospitals tolerate fragmented workflows rather than introducing a new software layer [xrlabs.ai, retrieved].

The edge visible from public evidence is clinical credibility paired with an integration-first product story, but the durability of that edge is not yet settled. Founder and CEO Dr. Ali Haddad is described publicly as a neurosurgeon, and Omar Ishrak, former Medtronic chairman and CEO, joined as chair alongside the seed round, which gives XRlabs unusual domain signaling for a young company selling into a conservative environment [Business Wire, October 2026] [LinkedIn, retrieved 2026]. If the product really runs across installed equipment rather than requiring replacement, that lowers adoption friction and could make XRlabs relevant to hospitals that cannot justify major capital refreshes [xrlabs.ai, retrieved] [Citybiz, October 2026]. Still, most of that advantage looks perishable until it is reinforced by named hospital references, repeat deployment evidence, or regulatory milestones in the UK, Europe, and the U.S., all of which the company said it plans to pursue with the new capital [Business Wire, October 2026].

The main exposure is that XRlabs does not appear to own the hardware channel, the procurement relationship, or a publicly documented installed base at scale. That matters because incumbent medtech vendors can bundle software with existing equipment contracts, service relationships, and regulatory infrastructure, while hospitals can default to the vendor already in the room even if that vendor's software is narrower in scope [Citybiz, October 2026]. XRlabs also appears exposed to the limits of proof: more than 100 surgical cases across three continents is a notable early signal, but it is still a small public evidence base relative to the validation usually required for enterprise clinical software, and the reported case count does not by itself establish routine usage, renewal strength, or departmental standardization [Business Wire, October 2026] [MobiHealthNews] [MPO-Mag].

The most plausible 18-month scenario is a market that stays open, but only for companies that can convert demonstrations into institutional adoption. Winner if X: XRlabs, if it can use the October 2026 seed financing to turn its cross-platform positioning into published clinical evidence, named reference sites, and at least a modest regulatory path that makes procurement easier for NHS and U.S. hospital buyers [Business Wire, October 2026] [Axios, October 2026]. Loser if Y: XRlabs, if incumbent device makers close enough of the workflow gap inside their own ecosystems that hospitals decide a single-vendor solution is safer than adding a separate intelligence layer, especially where procurement teams prioritize service continuity over software flexibility [xrlabs.ai, retrieved] [Citybiz, October 2026].

Opportunity

PUBLIC

The prize here is unusually large if XRlabs can become the software layer that sits across operating-room hardware already installed in hospitals, because that would place it inside a high-value clinical workflow without asking providers to rip out incumbent systems [Business Wire, October 2026] [xrlabs.ai, retrieved].

The headline opportunity is not simply another planning tool for surgeons. It is the chance to become default infrastructure for intraoperative intelligence, starting in complex surgery and expanding wherever live video, imaging, and device data need to be unified in real time [xrlabs.ai, retrieved] [Business Wire, October 2026]. That outcome is still early, but it is at least reachable from the evidence on hand: the company says its platform runs as a device-agnostic layer on equipment hospitals already own, reports usage in more than 100 surgical cases across three continents, and has attracted an $8.4 million seed round led by Playground Global with Omar Ishrak, former Medtronic chairman and CEO, joining as board chair [Business Wire, October 2026] [Citybiz, October 2026] [MobiHealthNews]. For a startup selling into the operating room, those signals matter because integration burden, clinical credibility, and strategic distribution are usually the gating constraints.

A second reason the upside is real is that XRlabs appears to have products on both sides of the surgical workflow. XRlabs SIM is described as turning CT and MRI scans into interactive 3D digital twins for planning, while SurgicalOS is described as fusing scope video, navigation, and intraoperative imaging into an anatomy-aware operating-room view [xrlabs.ai, retrieved]. If both products gain adoption, the company is not just selling a point solution. It is trying to own the data and workflow handoff from preoperative planning into live surgery, which is where software platforms tend to gain staying power.

Scenario	What happens	Catalyst	Why it's plausible
Planning-to-OR platform	XRlabs turns SIM and SurgicalOS into a linked workflow, so hospitals adopt it first for planning and then standardize on it during live procedures	Additional clinical evidence and regulatory progress in the UK, Europe, and the US, which the company said the seed capital will support [Business Wire, October 2026]	The public product set already spans planning and intraoperative support, and the company says the new financing will fund regulatory work and clinical expansion [xrlabs.ai, retrieved] [Business Wire, October 2026]
Embedded intelligence layer for device makers	XRlabs becomes the software partner that helps incumbent equipment manufacturers add anatomy-aware intelligence without replacing installed hardware	A formal device-manufacturer partnership or OEM-style distribution agreement, consistent with the company's stated work with device partners [xrlabs.ai, retrieved]	The core pitch is explicitly device-agnostic and built to run on existing equipment, which is structurally easier for hospitals and potentially useful to manufacturers defending installed bases [xrlabs.ai, retrieved] [Citybiz, October 2026]
Complex-surgery wedge expands outward	The company wins credibility in neurosurgery and other technically demanding cases, then broadens into adjacent specialties where imaging-rich workflows are already standard	More landmark cases like the AI-designed implant work tied to craniopagus twin separation and broader case volume beyond the reported 100-plus procedures [Yahoo Finance] [Morningstar]	The company already markets from a high-acuity wedge, and it has third-party pickup around a clinically notable use case plus a TIME recognition for XRlabs SIM [TIME, October 2025] [Yahoo Finance]

What compounding could look like is straightforward, even if it is not yet proven at scale. Each deployment can generate three reinforcing assets: a deeper integration footprint in the operating room, more clinical evidence that the system improves visualization and workflow, and a richer stream of surgical imaging and workflow data to improve future software performance [Business Wire, October 2026] [xrlabs.ai, retrieved]. In medtech software, that matters because once a team is trained on a planning interface and an intraoperative view, switching costs rise through workflow familiarity, device integration, and surgeon preference rather than through pure procurement friction.

There is also a distribution flywheel available if XRlabs can satisfy both hospitals and device manufacturers. A hospital buyer wants software that works with existing equipment; a manufacturer wants its installed base to remain useful and more intelligent; a surgeon wants fewer disconnected screens and more anatomy-aware context during a procedure [xrlabs.ai, retrieved]. If XRlabs can serve all three without forcing capital replacement, every new device relationship could lower future sales friction, and every clinically visible case could improve trust with the next hospital account. The reported use in more than 100 surgical cases on three continents suggests that this loop has started, even if the public evidence does not yet show account density or renewal behavior [Business Wire, October 2026] [MPO-Mag].

The size of the win is best framed qualitatively because no credible public market-size figure or directly comparable valuation is established in the supplied sources. Even so, the outer bound is clear enough: if XRlabs becomes a standard software and data layer across complex surgical environments, it would resemble core workflow infrastructure rather than a single-feature application, with strategic value to both providers and large medtech incumbents [xrlabs.ai, retrieved] [Business Wire, October 2026]. In that scenario, not a forecast, the company could plausibly grow into a strategically significant asset in surgical technology, particularly if regulatory progress, clinical evidence, and OEM distribution line up behind the current product architecture [Business Wire, October 2026] [Citybiz, October 2026].

Company-stated, unverified -- This section relies materially on company statements carried by Business Wire and the company website, with partial corroboration from Citybiz, TIME-linked company materials, Yahoo Finance, Morningstar, and MPO-Mag.

Sources